Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

Hepatology (Baltimore, Md.) - 1 Sept 2003

Bressler Brian L, Guindi Maha, Tomlinson George, Heathcote Jenny

Abstract excerpt

The aim of this study was to determine if body mass index (BMI) was an independent predictor of response to antiviral treatment in patients with chronic hepatitis C. A retrospective review was performed of all patients at a single center with chronic hepatitis C treated with antiviral medication from 1989 to 2000. A sustained response was defined as either negative hepatitis C virus (HCV) RNA by polymerase chain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Body Mass Index

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Interferons

Share to Liver Cirrhosis

Share to Ribavirin

Share to Treatment Failure

Source

Identifiers

PMID: 12939590
DOI: 10.1053/jhep.2003.50350

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.PMID 12939590Read ↗

Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3.Semantic proximity Read ↗

In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy.Semantic proximity Read ↗

Factors Associated with Insulin Resistance in Patients with Chronic HCV Genotype 1 Infection without Obesity or Type 2 Diabetes.Semantic proximity Read ↗

Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.Semantic proximity Read ↗

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.Semantic proximity Read ↗

Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C.Semantic proximity Read ↗

Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4.Semantic proximity Read ↗

Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C.Semantic proximity Read ↗

Serum HCV RNA level is not associated with insulin resistance and metabolic syndrome in chronic hepatitis C patients with genotype 1 or 2 infection.Semantic proximity Read ↗

Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.Semantic proximity Read ↗

Influence of body mass index, cholesterol, triglycerides and steatosis on pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C in patients transplanted for HCV and alcoholic cirrhosis.Semantic proximity Read ↗

Serum leptin and ghrelin in chronic hepatitis C patients with steatosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.